Controversial Avastin Spit and Ship Study to Help Triple Negative Breast Cancer Patients
By Timothy Boyer for eMaxHealth.com
Undeterred by the U.S. Food and Drug Administration (FDA) removal of Avastin for breast cancer, makers of the drug are now seeking breast cancer patients who have previously used Avastin to provide saliva samples in a spit and ship study titled “The InVite Study” to determine if there is a subset of women with breast cancer—such as those diagnosed with triple negative breast cancer—who may still benefit from Avastin.
New Type of Chemotherapy Bypasses Healthy Cells to Decrease Negative Side Effects: Click “Next” below!
